These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 16447111)

  • 1. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America.
    Talbot GH; Bradley J; Edwards JE; Gilbert D; Scheld M; Bartlett JG;
    Clin Infect Dis; 2006 Mar; 42(5):657-68. PubMed ID: 16447111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America.
    Spellberg B; Guidos R; Gilbert D; Bradley J; Boucher HW; Scheld WM; Bartlett JG; Edwards J;
    Clin Infect Dis; 2008 Jan; 46(2):155-64. PubMed ID: 18171244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America.
    Boucher HW; Talbot GH; Bradley JS; Edwards JE; Gilbert D; Rice LB; Scheld M; Spellberg B; Bartlett J
    Clin Infect Dis; 2009 Jan; 48(1):1-12. PubMed ID: 19035777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibiotic resistance. An impending crisis.
    Mah MW; Memish ZA
    Saudi Med J; 2000 Dec; 21(12):1125-9. PubMed ID: 11360084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Late stage antibacterial drugs in the clinical pipeline.
    Projan SJ; Bradford PA
    Curr Opin Microbiol; 2007 Oct; 10(5):441-6. PubMed ID: 17950658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Legislative mandates for use of active surveillance cultures to screen for methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: Position statement from the Joint SHEA and APIC Task Force.
    Weber SG; Huang SS; Oriola S; Huskins WC; Noskin GA; Harriman K; Olmsted RN; Bonten M; Lundstrom T; Climo MW; Roghmann MC; Murphy CL; Karchmer TB
    Am J Infect Control; 2007 Mar; 35(2):73-85. PubMed ID: 17327185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Societal costs versus savings from wild-card patent extension legislation to spur critically needed antibiotic development.
    Spellberg B; Miller LG; Kuo MN; Bradley J; Scheld WM; Edwards JE
    Infection; 2007 Jun; 35(3):167-74. PubMed ID: 17565458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BAD BUGS, NO DRUGS 2002-2020: PROGRESS, CHALLENGES, AND CALL TO ACTION.
    Boucher HW
    Trans Am Clin Climatol Assoc; 2020; 131():65-71. PubMed ID: 32675844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Control of human parasitic diseases: Context and overview.
    Molyneux DH
    Adv Parasitol; 2006; 61():1-45. PubMed ID: 16735161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination drugs, an emerging option for antibacterial therapy.
    Cottarel G; Wierzbowski J
    Trends Biotechnol; 2007 Dec; 25(12):547-55. PubMed ID: 17997179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reducing antimicrobial resistance through appropriate antibiotic usage in Singapore.
    Hsu LY; Kwa AL; Lye DC; Chlebicki MP; Tan TY; Ling ML; Wong SY; Goh LG
    Singapore Med J; 2008 Oct; 49(10):749-55. PubMed ID: 18946605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial resistance in major pathogens of hospital-acquired pneumonia in Asian countries.
    Lagamayo EN
    Am J Infect Control; 2008 May; 36(4 Suppl):S101-8. PubMed ID: 18468549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Empty antibiotic pipeline critically endangers public: IDSA report.
    James JS
    AIDS Treat News; 2004 Aug; (404):7. PubMed ID: 15484367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Future antibiotics scenarios: is the tide starting to turn?
    Theuretzbacher U
    Int J Antimicrob Agents; 2009 Jul; 34(1):15-20. PubMed ID: 19342202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emergency medicine and the public's health: emerging infectious diseases.
    Saks MA; Karras D
    Emerg Med Clin North Am; 2006 Nov; 24(4):1019-33. PubMed ID: 16982350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economics of new oncology drug development.
    DiMasi JA; Grabowski HG
    J Clin Oncol; 2007 Jan; 25(2):209-16. PubMed ID: 17210942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emergence of multidrug-resistant Streptococcus pneumoniae: report from the SENTRY Antimicrobial Surveillance Program (1999-2003).
    Johnson DM; Stilwell MG; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2006 Sep; 56(1):69-74. PubMed ID: 16546341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The research agenda of the National Institute of Allergy and Infectious Diseases for antimicrobial resistance.
    Peters NK; Dixon DM; Holland SM; Fauci AS
    J Infect Dis; 2008 Apr; 197(8):1087-93. PubMed ID: 18419527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of poverty in antimicrobial resistance.
    Planta MB
    J Am Board Fam Med; 2007; 20(6):533-9. PubMed ID: 17954860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.